Abstract:
This study aimed at determining the presence and type of specific antibodies among multi
transfused oncology patients, that causes alloimmunization, the ABO and Rhesus blood group that is
most affected by alloimmunization among multi transfused oncology patients, gender and age group
that is most alloimmunized. The research study was conducted using experimental design. The
sample size of the study was one hundred and sixty-two (162). Oncology patients were obtained
through non-Probabilistic. The study used Non probabilistic and consecutive sampling which
included all the subjects that were available. The one sixty-two (162) samples of multitransfused
oncology patients who met the inclusion criteria were screened to determine the presence of
alloantibodies. Out of 162 screened samples 152 had no alloantibodies, 10 were positive on antibody
screening test resulting to Positivity rate of 10/162(6%). The findings of the identification of the type
of alloantibodies in samples of multitransfused oncology patients, were as follows: out of ten (10)
samples that had alloantibodies, five (5) samples had anti E, 5/10(50%), three (3) sample had anti K
that is 3/10(30%) anti C, and anti D each had one alloantibody 1/10(10%). Alloimmunization are
attributed to lack of proper management following potential sensitization events before and after
blood transfusions. There is need to improve on the current practices of blood grouping and cross
match in most of our Kenyan hospitals.
Description:
This study aimed at determining the presence and type of specific antibodies among multi
transfused oncology patients, that causes alloimmunization, the ABO and Rhesus blood group that is
most affected by alloimmunization among multi transfused oncology patients, gender and age group
that is most alloimmunized. The research study was conducted using experimental design. The
sample size of the study was one hundred and sixty-two (162). Oncology patients were obtained
through non-Probabilistic. The study used Non probabilistic and consecutive sampling which
included all the subjects that were available. The one sixty-two (162) samples of multitransfused
oncology patients who met the inclusion criteria were screened to determine the presence of
alloantibodies. Out of 162 screened samples 152 had no alloantibodies, 10 were positive on antibody
screening test resulting to Positivity rate of 10/162(6%). The findings of the identification of the type
of alloantibodies in samples of multitransfused oncology patients, were as follows: out of ten (10)
samples that had alloantibodies, five (5) samples had anti E, 5/10(50%), three (3) sample had anti K
that is 3/10(30%) anti C, and anti D each had one alloantibody 1/10(10%). Alloimmunization are
attributed to lack of proper management following potential sensitization events before and after
blood transfusions. There is need to improve on the current practices of blood grouping and cross
match in most of our Kenyan hospitals.